Skip to main content

Table 1 Pharmacokinetic parameters of talinolol (50 mg dose)

From: Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters

  

MZ twin pairs

DZ twin pairs

Parameter

Unit

Mean ± SD

Median (Min–Max)

Ratio Max/Min

Mean ± SD

Median (Min–Max)

Ratio Max/Min

Clearance (Cl/F)

l/min

0.97 ± 0.42

0.87 (0.30–2.64)

8.8

0.82 ± 0.27

0.76 (0.37–1.39)

3.8

Clearance per body weight (Cl/F/kg)

ml/min/kg

14.4 ± 5.51

13.5 (6.16–38.5)

6.3

12.1 ± 3.8

11.6 (6.96–19.9)

2.9

AUCinfinity

mg*min/l

62.8 ± 25.2

60.2 (22.8–171.1)

7.5

71.3 ± 23.8

68.6 (37.6–135.8)

3.6

AUC7h

mg*min/l

20.1 ± 9.10

19.3 (7.36–62.7)

8.5

24.9 ± 9.93

23.6 (11.7–54.8)

4.7

Central volume of distribution (Vz)

l

1115 ± 510

1006 (293–2549)

8.7

889 ± 449

747 (302–2169)

7.2

Maximum plasma concentration (Cmax)

μg/l

94.3 ± 47.0

84.9 (23.3–258)

11.1

124 ± 55.4

115 (51.9–269)

5.2

Time of maximum plasma concentration (tmax)

h

2.6 ± 0.7

2.6 (1.2–4.1)

3.4

2.6 ± 0.8

2.7 (1.0–3.9)

3.9

Terminal elimination half life (t1/2)

h

13.3 ± 4.0

12.2 (7.9–30.0)

3.8

11.9 ± 2.7

11.5 (7.2–18.1)

4.3

  1. MZ monozygotic, DZ dizygotic, SD standard deviation. All pharmacokinetic parameters were calculated with the mean of up to three study days for each subject